Johnson & Johnson Announces Two-year Data From Its Phase 3 ICONIC-TOTAL Study Of ICOTYDE On High-Impact Plaque Psoriasis Sites; 60% Of Patients With Scalp Psoriasis And 89% With Genital Psoriasis Achieved Site-Specific Complete Skin Clearance At Week 112